{"id":4712,"date":"2026-09-23T17:07:18","date_gmt":"2026-09-23T17:07:18","guid":{"rendered":"https:\/\/www.europesays.com\/conflicts\/4712\/"},"modified":"2026-09-23T17:07:18","modified_gmt":"2026-09-23T17:07:18","slug":"flagship-pentagon-astrazeneca-gsk-readout-newsletter","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/conflicts\/4712\/","title":{"rendered":"Flagship, Pentagon, AstraZeneca, GSK: Readout Newsletter"},"content":{"rendered":"<p class=\"author-bio\">Elaine\u2019s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes <a href=\"https:\/\/www.statnews.com\/signup\/readout\/\" rel=\"nofollow noopener\" target=\"_blank\">The Readout newsletter<\/a>, and co-hosts STAT\u2019s weekly biotech podcast, <a href=\"https:\/\/www.statnews.com\/category\/readout-loud\/\" rel=\"nofollow noopener\" target=\"_blank\">The Readout Loud<\/a>. You can reach Elaine on Signal at elaineywchen.70.<\/p>\n<p class=\"wp-block-paragraph\">Want to stay on top of the science and politics driving biotech today?\u00a0<a href=\"https:\/\/www.statnews.com\/signup\/readout\/\" rel=\"nofollow noopener\" target=\"_blank\">Sign up<\/a>\u00a0to get our biotech newsletter in your inbox.<\/p>\n<p class=\"wp-block-paragraph\">Good morning. STAT is hosting a virtual event tomorrow on the future of biosimilars. Check it out <a href=\"https:\/\/www.statnews.com\/event\/biosimilars-what-is-next-virtual-event-sept-2026\/\" rel=\"nofollow noopener\" target=\"_blank\">here<\/a>.<\/p>\n<p>VCs rush to invest in osteoporosis drugs<\/p>\n<p class=\"wp-block-paragraph\">Developing drugs for brittle bones has long been a difficult endeavor, due to safety concerns and regulatory barriers. But now with new guidance from the FDA, pharma companies are returning to osteoporosis research, and investors are getting interested.<\/p>\n<p class=\"restricted-text\">STAT+ Exclusive Story<\/p>\n<p class=\"restricted-login\">Already have an account? <a href=\"https:\/\/www.statnews.com\/login\/\" data-stat-login=\"\" data-stat-paywall-cta=\"breaker login cta\" rel=\"nofollow noopener\" target=\"_blank\">Log in<\/a><\/p>\n<p>\t\t\t<img decoding=\"async\" class=\"restricted-content-breaker-bg\" src=\"https:\/\/www.europesays.com\/conflicts\/wp-content\/uploads\/2026\/09\/stat-plus-breaker-bg.png\" alt=\"STAT+\"\/><\/p>\n<p>\t\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n\t\t\t\t\t\t<img decoding=\"async\" class=\"stat-plus-logo\" src=\"https:\/\/www.statnews.com\/wp-content\/themes\/stat\/images\/stat-plus-logo-white.svg\" alt=\"STAT+\"\/><br \/>\n\t\t\t\t\t<\/a><\/p>\n<p>\t\t\t\tThis article is exclusive to STAT+ subscribers<br \/>\n\t\t\t\tUnlock this article \u2014 plus in-depth analysis, newsletters, premium events, and news alerts.<\/p>\n<p class=\"restricted-content-breaker-wrapper-cta mobile\">Already have an account? <a href=\"https:\/\/www.statnews.com\/login\/\" data-stat-login=\"\" data-stat-paywall-cta=\"breaker login cta mobile\" rel=\"nofollow noopener\" target=\"_blank\">Log in<\/a><\/p>\n<p>\t\t\t\t\t\tIndividual plans<\/p>\n<p>\t\t\t\t\t\tGroup plans<\/p>\n<p>\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" class=\"stat-button view-all\" data-stat-paywall-cta=\"breaker view all plans\" aria-label=\"View All Plans\" rel=\"nofollow noopener\" target=\"_blank\">View All Plans<\/a><\/p>\n<p class=\"restricted-content-text\">\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n<p>\t\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" class=\"stat-button restricted-button\" data-stat-paywall-cta=\"breaker subscribe cta 1\" rel=\"nofollow noopener\" target=\"_blank\">Subscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Elaine\u2019s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected&hellip;\n","protected":false},"author":2,"featured_media":4713,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[4374,4375,4376,4377,4378,20,216,215,4379,4380,480],"class_list":["post-4712","post","type-post","status-publish","format-standard","has-post-thumbnail","category-us-wars","tag-biotech","tag-biotechnology","tag-drug-development","tag-drug-prices","tag-drug-pricing","tag-news","tag-pentagon","tag-pentagon-news","tag-pharmaceuticals","tag-policy","tag-research"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@conflicts\/117321456016157952","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/conflicts\/wp-json\/wp\/v2\/posts\/4712","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/conflicts\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/conflicts\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/conflicts\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/conflicts\/wp-json\/wp\/v2\/comments?post=4712"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/conflicts\/wp-json\/wp\/v2\/posts\/4712\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/conflicts\/wp-json\/wp\/v2\/media\/4713"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/conflicts\/wp-json\/wp\/v2\/media?parent=4712"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/conflicts\/wp-json\/wp\/v2\/categories?post=4712"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/conflicts\/wp-json\/wp\/v2\/tags?post=4712"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}